Your taste in music is weird. Maybe you just can’t stop listening to that power ballad, or you’ve wondered about your bewildering weakness for yodeling. And maybe, just maybe, nobody understands your all-consuming obsession with Steely Dan, the greatest band of all time.
Scots experts have discovered the brain’s “rhythmic fingerprints”, which could be used to diagnose and treat conditions ranging from post traumatic stress disorder (PTSD) to dementia.
Brain oscillations – often known as brain waves – caused by electrical waves pulsing through grey matter have puzzled experts since their discovery by German psychiatrist Hans Berger in 1924.
Neuroscientists from Glasgow University have now found that each area of the brain has its own characteristic mix of rhythms, which could be read like a fingerprint using magnetic waves.
Physicists have confirmed the existence of a new form of atomic nuclei, and the fact that it’s not symmetrical challenges the fundamental theories of physics that explain our Universe.
But that's not as bad as it sounds, because the discovery could help scientists solve one of the biggest mysteries in theoretical physics - where is all the dark matter? - and could also explain why travelling backwards in time might actually be impossible.
In the last few years, several groups have announced that their facial recognition systems have achieved near-perfect accuracy rates, performing better than humans at picking the same face out of the crowd.
But those tests were performed on a dataset with only 13,000 images—fewer people than attend an average professional U.S. soccer game. What happens to their performance as those crowds grow to the size of a major U.S. city?
The US Food and Drug Administration on Monday approved the first human trial of an experimental Zika vaccine, according to a joint announcement by the two companies behind the new therapy.
The companies, Inovio Pharmaceuticals, Inc., based in Pennsylvania, and GeneOne Life Science, Inc., based in South Korea, said that their DNA-based vaccine candidate, dubbed GLS-5700, will be given to 40 people in a phase I trail. The trial will start “in the next weeks,” the companies said, and could yield results later this year.